Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement

on behalf of the American Cancer Society Guideline Development Group

Research output: Contribution to journalReview articlepeer-review

57 Scopus citations


Answer questions and earn CME/CNE. The American Cancer Society (ACS) reviewed and updated its guideline on human papillomavirus (HPV) vaccination based on a methodologic and content review of the Advisory Committee on Immunization Practices (ACIP) HPV vaccination recommendations. A literature review was performed to supplement the evidence considered by the ACIP and to address new vaccine formulations and recommendations as well as new data on population outcomes since publication of the 2007 ACS guideline. The ACS Guideline Development Group determined that the evidence supports ACS endorsement of the ACIP recommendations, with one qualifying statement related to late vaccination. The ACS recommends vaccination of all children at ages 11 and 12 years to protect against HPV infections that lead to several cancers and precancers. Late vaccination for those not vaccinated at the recommended ages should be completed as soon as possible, and individuals should be informed that vaccination may not be effective at older ages. CA Cancer J Clin 2016;66:375–385.

Original languageEnglish (US)
Pages (from-to)375-385
Number of pages11
JournalCA Cancer Journal for Clinicians
Issue number5
StatePublished - Sep 1 2016

Bibliographical note

Publisher Copyright:
© 2016 American Cancer Society


  • Advisory Committee on Immunization Practices
  • American Cancer Society
  • cancer prevention
  • guideline
  • human papillomavirus (HPV)
  • vaccine


Dive into the research topics of 'Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement'. Together they form a unique fingerprint.

Cite this